Analyzing Allurion Technologies (NYSE:ALUR) & Quanterix (NASDAQ:QTRX)

Allurion Technologies (NYSE:ALUR) and Quanterix (NASDAQ:QTRX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of current recommendations for Allurion Technologies and Quanterix, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allurion Technologies	1	1	1	0	2.00
Quanterix	1	2	0	0	1.67

Allurion Technologies presently has a consensus price target of $45.00, indicating a potential upside of 7,658.62%. Quanterix has a consensus price target of $4.00, indicating a potential upside of 14.61%. Given Allurion Technologies’ stronger consensus rating and higher possible upside, research analysts plainly believe Allurion Technologies is more favorable than Quanterix.

Insider and Institutional Ownership

21.4% of Allurion Technologies shares are owned by institutional investors. Comparatively, 86.5% of Quanterix shares are owned by institutional investors. 8.1% of Allurion Technologies shares are owned by company insiders. Comparatively, 1.5% of Quanterix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Allurion Technologies and Quanterix”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allurion Technologies	$17.21 million	0.51	-$7.20 million	($2.03)	-0.29
Quanterix	$144.74 million	1.14	-$107.15 million	($2.36)	-1.48

Allurion Technologies has higher earnings, but lower revenue than Quanterix. Quanterix is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Allurion Technologies and Quanterix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Allurion Technologies	-199.96%	N/A	-77.13%
Quanterix	-71.86%	-23.92%	-17.66%

Volatility & Risk

Allurion Technologies has a beta of -0.13, indicating that its share price is 113% less volatile than the S&P 500. Comparatively, Quanterix has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500.

Summary

Allurion Technologies beats Quanterix on 8 of the 14 factors compared between the two stocks.

About Allurion Technologies

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.